Catalent (also known as Catalent Pharma Solutions) is a global contract development and manufacturing organization (CDMO) serving pharmaceutical, biotechnology, and consumer health companies. It provides services spanning early-stage development, scale-up, commercial manufacturing, and supply chain support.
The company’s capabilities cover drug formulation and delivery technologies, including softgel and animal-free softgel capsules, oral solid dose forms and orally disintegrating tablets, sterile injectables, and biologics development and fill-finish. Catalent also offers cell and gene therapy services, including viral vector development and manufacturing, as well as inhalation and nasal drug products, clinical packaging and distribution, and analytical testing. It supports highly potent compounds and provides technology transfer and lifecycle management across a global network of GMP facilities in North America, Europe, and Asia.
Catalent originated from the 2007 carve-out of Cardinal Health’s Pharmaceutical Technologies and Services business and became a publicly listed company in 2014. It is headquartered in Somerset, New Jersey, USA.